Hikma Pharmaceuticals Plc Acquisition (6414Y)

TIDMHIK

RNS Number : 6414Y

Hikma Pharmaceuticals Plc

17 January 2022

Hikma expands into Canada with acquisition of Teligent sterile injectable assets

London, 17 January 2022 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.

The acquisition marks Hikma's expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Riad Mishlawi, President of Hikma Injectables, commented, "This acquisition further expands our portfolio of essential sterile injectable medicines and gives Hikma an entry into the highly attractive Canadian injectables market. The combination of our sales and marketing expertise and this portfolio of exciting products will enable us to expand our North American business and develop a solid position in this important market."

In October 2021, Teligent filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code. As part of this process, Teligent initiated a sale of its core assets, following which Hikma has agreed to acquire Teligent's Canadian assets.

- ENDS -

Enquiries:

Hikma (Investors):

 
Susan Ringdal 
 EVP, Strategic Planning and Global   +44 (0)20 7399 2760/ +44 (0)7776 
 Affairs                               477050 
Guy Featherstone                      +44 (0)20 3892 4389/ +44 (0)7795 
 Senior Investor Relations Manager     896738 
Layan Kalisse                         +44 (0)20 7399 2788/ +44 (0)7970 
 Investor Relations Analyst            709912

Teneo (Press):

 
                             +44 (0)7703 330 269 
Charles Armitstead 
 
 US Media 
 Steven Weiss/David Belian    +1 732 788 8279/ +1 848 254 4875

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQUBSNRUVUAARR

(END) Dow Jones Newswires

January 17, 2022 02:00 ET (07:00 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024